Full phase II results have not been put out. Leo tried giving some bits to shareholders early instead of waiting until he could present full results. Full results will open some eyes.
If not for phase II, the phase III results will achieve substantially higher share price. The trials for antibiotics are short. Either way, 2015 is our year for great share price movement. And, that's just for Brilacidin for ABSSSI. It's a game changer by being effective at only one dose.
And, we also have a lot more going on.
I'm quite anxious to see the posters presented at the Biotech Showcase.